Scarica l'app Stockscreener
14.12
0.36%
0.05
Precedente Chiudi:
$14.07
Aprire:
$14
Volume 24 ore:
621.06K
Relative Volume:
0.41
Capitalizzazione di mercato:
$1.55B
Reddito:
$-249.00K
Utile/perdita netta:
$-187.60M
Rapporto P/E:
-5.648
EPS:
-2.5
Flusso di cassa netto:
$-201.88M
1 W Prestazione:
+1.00%
1M Prestazione:
+12.06%
6M Prestazione:
+70.12%
1 anno Prestazione:
+293.31%
Intervallo 1D:
$13.82
$14.45
Intervallo di 1 settimana:
$13.58
$15.11
Portata 52W:
$2.865
$17.49
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Nome
Amylyx Pharmaceuticals Inc
Settore
Telefono
617-683-0917
Indirizzo
43 THORNDIKE STREET, CAMBRIDGE
Compare AMLX vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
14.12 | 1.55B | -249.00K | -187.60M | -201.88M | -2.50 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.46 | 58.03B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.65 | 55.37B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.20 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.98 | 39.50B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
473.66 | 20.50B | 3.13B | 1.27B | 1.12B | 26.39 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-06-24 | Iniziato | Guggenheim | Buy |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2025-05-30 | Iniziato | TD Cowen | Buy |
| 2025-04-07 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-11-18 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-03-18 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-11 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-07-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2023-01-05 | Iniziato | BofA Securities | Buy |
| 2022-05-25 | Iniziato | Citigroup | Buy |
| 2022-04-01 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie
Amylyx Pharmaceuticals (AMLX) Stock Analysis: Exploring a 50% Upside Potential in Neurodegenerative Drug Development - DirectorsTalk Interviews
Research Analysts Set Expectations for AMLX FY2029 Earnings - MarketBeat
Is Amylyx Pharmaceuticals Inc. stock a good pick for beginnersIndex Update & Weekly Setup with ROI Potential - mfd.ru
FMR LLC's Strategic Acquisition of Amylyx Pharmaceuticals Inc Sh - GuruFocus
HC Wainwright Issues Positive Forecast for Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price - MarketBeat
Amylyx stock price target raised to $28 from $20 at H.C. Wainwright - Investing.com Nigeria
Amylyx stock price target raised to $28 from $20 at H.C. Wainwright By Investing.com - Investing.com South Africa
Top Amylyx Executives Quietly Unload a Wave of Company Shares - TipRanks
Amylyx Pharmaceuticals Co-Chief Executive Sells AMLX 138K Shares for $1.9 Million - The Globe and Mail
Amylyx Pharmaceuticals, Inc. (AMLX): Investor Outlook With A 36% Potential Upside - DirectorsTalk Interviews
HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - Finviz
HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHO - GuruFocus
H.C. Wainwright, Leerink Partners, and TD Cowen Reaffirm ‘Buy’ Ratings on Amylyx Pharmaceuticals, Inc. (AMLX) - MSN
INVESTOR ALERT AND NOTICE: Kaskela Law Firm Announces Investigation of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) and Encourages Long-Term Amylyx Investors with Losses to Contact the Firm - ACCESS Newswire
Trend Report: Is Amylyx Pharmaceuticals Inc benefiting from interest rate changesWeekly Trade Recap & Community Trade Idea Sharing - baoquankhu1.vn
Amylyx Pharmaceuticals: Back From The Dead (NASDAQ:AMLX) - Seeking Alpha
FY2030 Earnings Estimate for AMLX Issued By HC Wainwright - MarketBeat
Is Amylyx Pharmaceuticals Inc still a buy after recent gainsJuly 2025 Chart Watch & Entry Point Strategy Guides - baoquankhu1.vn
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Amylyx nominates AMX0318 as long-acting GLP-1 candidate for rare endocrine disorders - MSN
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Down 4.5%What's Next? - MarketBeat
How Investors May Respond To Gubra (CPSE:GUBRA) Securing Amylyx GLP-1 Milestones And Royalty Upside - Yahoo Finance
Amylyx Pharmaceuticals stock hits 52-week high at $16.96 By Investing.com - Investing.com Nigeria
Amylyx Pharma Hits New HighDelivers Over 160% Gain In 7 Months - Nasdaq
Amylyx Pharmaceuticals (NASDAQ:AMLX) Reaches New 52-Week HighTime to Buy? - MarketBeat
January 2027 Options Now Available For Amylyx Pharmaceuticals (AMLX) - Nasdaq
Amylyx Pharmaceuticals stock hits 52-week high at $16.96 - Investing.com
Amylyx pharma co-CEO Klee sells $1.88 million in AMLX stock - Investing.com Nigeria
Amylyx Pharmaceuticals Inc (AMLX) Shares Up 8.85% on Jan 20 - GuruFocus
Amylyx Pharmaceuticals (AMLX) Valuation After AMX0318 Rare Disease Pipeline Update - simplywall.st
Amylyx pharma co-CEO Klee sells $1.88 million in AMLX stock By Investing.com - Investing.com India
Amylyx pharma co-CEO Cohen sells $1.87m in shares By Investing.com - Investing.com India
Amylyx Pharmaceuticals (NASDAQ:AMLX) CEO Sells $1,850,862.87 in Stock - MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) CEO Sells $27,300.42 in Stock - MarketBeat
Amylyx pharma co-CEO Cohen sells $1.87m in shares - Investing.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading 11.7% HigherHere's What Happened - MarketBeat
EV Market: Is Amylyx Pharmaceuticals Inc stock a good pick for beginnersWeekly Stock Recap & Pattern Based Trade Signal System - baoquankhu1.vn
Amylyx Nominates AMX0318 as Long-Acting GLP-1 Candidate for Rare Endocrine Disorders - Finviz
More Money In The Bank For Amylyx Pharmaceuticals Insiders Who Divested US$2.0m - 富途牛牛
Amylyx Pharmaceuticals Inc (AMLX) Trading 3.18% Higher on Jan 16 - GuruFocus
9 Overlooked Growth Stocks to Buy - Insider Monkey
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Up 6.5%What's Next? - MarketBeat
Insider Trends: Will Amylyx Pharmaceuticals Inc. stock sustain high P E ratios2025 Trading Recap & Fast Moving Stock Watchlists - Bộ Nội Vụ
Amylyx Pharmaceuticals (AMLX) Valuation Check As New GLP-1 Candidate AMX0318 Enters Development Stage - Yahoo Finance
Amylyx Pharmaceuticals (AMLX) announces the selection of AMX0318 as development candidate for PBH and other rare diseases - MSN
Amylyx Pharmaceuticals Inc Azioni (AMLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.19%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):